Commerzbank Aktiengesellschaft Bristol Myers Squibb CO Transaction History

Commerzbank Aktiengesellschaft

$4.29 Billion
Q1 2025

A detailed history of Commerzbank Aktiengesellschaft transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Commerzbank Aktiengesellschaft holds 13,526 shares of BMY stock, worth $635,316. This represents 0.02% of its overall portfolio holdings.

Number of Shares

13,526

Previous 13,526 -0.0%

Holding current value

$635,316

Previous $759,000 8.7%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$51.92 - $59.94 $188,936 - $218,121	3,639 Added 36.81%	13,526 $759,000
Q3 2024 Oct 22, 2024	BUY	$39.66 - $51.75 $129,846 - $169,429	3,274 Added 49.51%	9,887 $512,000
Q2 2024 Jul 22, 2024	BUY	$40.25 - $52.99 $22,177 - $29,197	551 Added 9.09%	6,613 $275,000
Q1 2024 May 10, 2024	BUY	$47.98 - $54.4 $96,103 - $108,963	2,003 Added 49.35%	6,062 $329,000
Q4 2023 Feb 01, 2024	BUY	$48.48 - $57.85 $196,780 - $234,813	4,059 New	4,059 $208,000
Q2 2020 Jul 21, 2020	SELL	$54.82 - $64.09 $2.62 Million - $3.07 Million	-47,853 Closed	0 $0
Q1 2020 Oct 03, 2024	BUY	$46.4 - $67.43 $1.95 Million - $2.83 Million	42,040 Added 635.72%	48,653 $2.71 Million
Q1 2020 Apr 29, 2020	SELL	$46.4 - $67.43 $32.9 Million - $47.8 Million	-708,875 Reduced 93.68%	47,853 $2.67 Million
Q4 2019 Oct 03, 2024	BUY	$49.21 - $64.19 $37 Million - $48.2 Million	750,915 Added 11355.13%	757,528 $48.6 Million
Q4 2019 Jan 17, 2020	SELL	$49.21 - $64.19 $6.09 Million - $7.94 Million	-123,764 Reduced 14.06%	756,728 $48.6 Million
Q3 2019 Oct 03, 2024	BUY	$42.77 - $50.71 $37.4 Million - $44.4 Million	874,679 Added 13226.66%	881,292 $44.7 Million
Q3 2019 Oct 17, 2019	BUY	$42.77 - $50.71 $6.06 Million - $7.18 Million	141,661 Added 19.17%	880,492 $44.7 Million
Q2 2019 Oct 03, 2024	BUY	$44.62 - $49.34 $32.7 Million - $36.2 Million	733,018 Added 11084.5%	739,631 $33.5 Million
Q2 2019 Jul 23, 2019	BUY	$44.62 - $49.34 $6.66 Million - $7.37 Million	149,312 Added 25.33%	738,831 $33.5 Million
Q1 2019 Oct 03, 2024	BUY	$45.12 - $53.8 $26.3 Million - $31.4 Million	583,706 Added 8826.64%	590,319 $28.2 Million
Q1 2019 May 13, 2019	BUY	$45.12 - $53.8 $2.07 Million - $2.47 Million	45,820 Added 8.43%	589,519 $28.1 Million
Q4 2018 Oct 03, 2024	BUY	$48.76 - $63.23 $26.2 Million - $34 Million	537,086 Added 8121.67%	543,699 $28.3 Million
Q4 2018 Feb 06, 2019	BUY	$48.76 - $63.23 $1.61 Million - $2.08 Million	32,957 Added 6.45%	543,699 $28.3 Million
Q3 2018 Oct 04, 2024	BUY	$55.19 - $62.25 $27.9 Million - $31.4 Million	505,154 Added 7638.8%	511,767 $31.8 Million
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $4.04 Million - $4.56 Million	-73,236 Reduced 12.54%	510,742 $31.7 Million
Q2 2018 Oct 04, 2024	BUY	$50.53 - $62.98 $29.2 Million - $36.4 Million	578,165 Added 8742.85%	584,778 $32.4 Million
Q2 2018 Aug 10, 2018	BUY	$50.53 - $62.98 $3.13 Million - $3.91 Million	62,006 Added 11.88%	583,978 $32.3 Million
Q1 2018 Oct 04, 2024	SELL	$59.92 - $68.98 $1.14 Million - $1.32 Million	-19,084 Reduced 3.52%	522,772 $33.1 Million
Q1 2018 May 01, 2018	SELL	$59.92 - $68.98 $1.14 Million - $1.32 Million	-19,084 Reduced 3.53%	521,972 $33 Million
Q4 2017 Oct 04, 2024	BUY	$59.94 - $65.35 $32.1 Million - $35 Million	535,243 Added 8093.8%	541,856 $33.2 Million
Q4 2017 Jan 26, 2018	SELL	$59.94 - $65.35 $509,549 - $555,540	-8,501 Reduced 1.55%	541,056 $33.2 Million
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $10,383 - $11,983	188 Added 0.03%	549,557 $35 Million
Q2 2017 Aug 09, 2017	BUY	N/A	549,369	549,369 $30.6 Million

Others Institutions Holding BMY

# of Institutions

2,808

Shares Held

1.59B

Call Options Held

25.9M

Put Options Held

23.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.9B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commerzbank Aktiengesellschaft , based on Form 13F filings with the SEC.

News

Stay updated on Commerzbank Aktiengesellschaft with notifications on news.

Account

Commerzbank Aktiengesellschaft Bristol Myers Squibb CO Transaction History